Guide
Tirzepatide Injection: Sites, Rotation and What Labelling Specifies
Approved labelling specifies subcutaneous injection into the abdomen, thigh or upper arm, once weekly on the same day, with the site rotated. The pen and the vial are dif
Approved labelling specifies subcutaneous injection into the abdomen, thigh or upper arm, once weekly on the same day, with the site rotated. The pen and the vial are different presentations of the same molecule, and the vial requires drawing the dose with a syringe — which is where dosing errors concentrate.
What does labelling specify?
| Field | What labelling says |
|---|---|
| Route | Subcutaneous |
| Sites | Abdomen, thigh, or upper arm |
| Rotation | Rotate the site with each injection |
| Frequency | Once weekly, same day each week |
| Timing with food | Any time of day, with or without meals |
| Storage | Refrigerated; see labelling for permitted room-temperature windows |
This is what the label states. It is not instruction for your regimen, which your prescriber and dispensing pharmacist set.
The auto-injector delivers a fixed dose. A multi-dose vial does not — you draw the volume yourself, and the concentration differs between products and between compounders.
That is the single largest practical difference between the brand pen and most compounded supply, and it is why the FDA has flagged dosing errors with compounded GLP-1 vials specifically. A vial priced at $186 and a pen priced at $449 are not the same task.
Ask any vial supplier for the concentration in milligrams per millilitre, in writing, and have the dispensing pharmacist confirm the volume that corresponds to your prescribed dose.
Does the presentation change the price?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
Most of the saving in the cheaper rows comes from the vial presentation rather than from the molecule. That is a real trade: lower cost, more room for user error.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Where do you inject tirzepatide?
Approved labelling specifies subcutaneous injection into the abdomen, thigh or upper arm, with the site rotated each time.
How often is tirzepatide injected?
Once weekly, on the same day each week, with or without food per labelling.
Why are vials riskier than pens?
A pen delivers a fixed dose; a vial requires drawing the volume yourself, and concentrations differ between products and compounders. The FDA has flagged dosing errors with compounded vials specifically.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Hims & Hers Tirzepatide ReviewProviders
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Zepbound vs MounjaroComparisons
- Tirzepatide for Type 2 DiabetesResearch
Related coverage
GLP-1 Tirzepatide Rank. “Tirzepatide Injection: Sites, Rotation and What Labelling Specifies.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-injection-guide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.